Navigation Links
Medivation Announces Participation in 29th Annual J.P. Morgan Healthcare Conference
Date:1/3/2011

SAN FRANCISCO, Jan. 3, 2011 /PRNewswire/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, at 10:30 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.

Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and Huntington diseases.

Live audio webcasts of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010
2. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
3. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimers Disease
4. Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4, 2009
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
8. Medivation Announces Pricing of Public Offering
9. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
10. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
11. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, FL ... live events series, “Stem Cell Therapy: The Next Phase in the Evolution of Medicine.” ... Stem Cell Research and Therapy Act, Okyanos maintains a mission to help “no-option” ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... peristaltic pump with patented ReNu single-use (SU) cartridge technology. Engineered by the ... feed pumps in SU tangential flow filtration (TFF), virus filtration (VF) and ...
(Date:3/22/2017)... 22, 2017  Personal Genome Diagnostics Inc. (PGDx) ... contract with the U.S. Department of Veterans Affairs ... with the company,s new CancerSELECT ™ 125 ... pan-cancer profiling test that includes microsatellite instability status ... response to checkpoint inhibitor immunotherapies. CancerSELECT 125 will ...
(Date:3/20/2017)... , ... March 20, 2017 , ... ... pharmaceutical and biotech companies, recently announced it will debut a brand new pressure ... City. The intelliVessel is controlled by a touch screen panel and features other ...
Breaking Biology Technology:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
Breaking Biology News(10 mins):